{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:59:19Z","timestamp":1789016359657,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770203"],"award-info":[{"award-number":["81770203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670135"],"award-info":[{"award-number":["81670135"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870109"],"award-info":[{"award-number":["81870109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing","doi-asserted-by":"crossref","award":["7162174"],"award-info":[{"award-number":["7162174"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00277-019-03636-8","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T07:22:21Z","timestamp":1549956141000},"page":"1267-1277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia"],"prefix":"10.1007","volume":"98","author":[{"given":"Xiao-Ning","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ji","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3334-9113","authenticated-orcid":false,"given":"Dai-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,12]]},"reference":[{"issue":"1","key":"3636_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-2141.2004.05318.x","volume":"129","author":"C Craddock","year":"2005","unstructured":"Craddock C, Tauro S, Moss P, Grimwade D (2005) Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 129(1):18\u201334","journal-title":"Br J Haematol"},{"issue":"23","key":"3636_CR2","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"M Duval","year":"2010","unstructured":"Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, de Lima M, Gupta V, Keating A, Lazarus HM, Litzow MR, Marks DI, Maziarz RT, Rizzieri DA, Schiller G, Schultz KR, Tallman MS, Weisdorf D (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 28(23):3730\u20133738","journal-title":"J Clin Oncol"},{"issue":"6","key":"3636_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/bjh.13912","volume":"172","author":"JM Middeke","year":"2016","unstructured":"Middeke JM, Herold S, R\u00fccker-Braun E, Berdel WE, Stelljes M, Kaufmann M, Sch\u00e4fer-Eckart K, Baldus CD, Stuhlmann R, Ho AD, Einsele H, R\u00f6sler W, Serve H, H\u00e4nel M, Sohlbach K, Klesse C, Mohr B, Heidenreich F, St\u00f6lzel F, R\u00f6llig C, Platzbecker U, Ehninger G, Bornh\u00e4user M, Thiede C, Schetelig J, Study Alliance Leukaemia (SAL) (2016) TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol 172(6):914\u2013922","journal-title":"Br J Haematol"},{"issue":"10","key":"3636_CR4","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1200\/JCO.2010.32.7742","volume":"29","author":"KH Metzeler","year":"2011","unstructured":"Metzeler KH, Maharry K, Radmacher MD, Mr\u00f3zek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD (2011) TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 29(10):1373\u20131381","journal-title":"J Clin Oncol"},{"issue":"1","key":"3636_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.bbmt.2015.07.030","volume":"22","author":"JS Ahn","year":"2016","unstructured":"Ahn JS, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD (2016) DNMT3A R882 mutation with FLT3-ITD positivity is an extremely poor prognostic factor in patients with normal-karyotype acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 22(1):61\u201370","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"3636_CR6","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","volume":"124","author":"RF Schlenk","year":"2014","unstructured":"Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, L\u00fcbbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, G\u00f6tze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Sp\u00e4th D, Benner A, Krauter J, Ganser A, D\u00f6hner H, D\u00f6hner K, German-Austrian AML Study Group (2014) Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood 124(23):3441\u20133449","journal-title":"Blood"},{"issue":"2","key":"3636_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11899-013-0153-6","volume":"8","author":"R Mawad","year":"2013","unstructured":"Mawad R, Lionberger JM, Pagel JM (2013) Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Curr Hematol Malig Rep 8(2):132\u2013140","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"3636_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1470-2045(09)70352-3","volume":"11","author":"B Friedrichs","year":"2010","unstructured":"Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, Beksac M, Hasenclever D, Soci\u00e9 G, Schmitz N (2010) Long-term outcome and late effects in patients transplanted with mobilized blood or bone marrow: a randomised trial. Lancet Oncol 11(4):331\u2013338","journal-title":"Lancet Oncol"},{"issue":"4","key":"3636_CR9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/j.1399-0012.2012.01626.x","volume":"26","author":"Y Wang","year":"2012","unstructured":"Wang Y, Liu DH, Fan ZP, Sun J, Wu XJ, Ma X, Xu LP, Liu KY, Liu QF, Wu DP, Huang XJ (2012) Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study. Clin Transpl 26(4):635\u2013643","journal-title":"Clin Transpl"},{"issue":"8","key":"3636_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/bmt.2011.213","volume":"47","author":"Y Wang","year":"2012","unstructured":"Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Zhang XH, Chen YH, Han W, Wang FR, Wang JZ, Yan CH, Huang XJ (2012) Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched\/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant 47(8):1099\u20131104","journal-title":"Bone Marrow Transplant"},{"key":"3636_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00277-018-3482-7","volume":"98","author":"XN Gao","year":"2018","unstructured":"Gao XN, Lin J, Wang SH, Huang WR, Li F, Li HH, Chen J, Wang LJ, Gao CJ, Yu L, Liu DH (2018) Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies. Ann Hematol 98:185\u2013193. \n                    https:\/\/doi.org\/10.1007\/s00277-018-3482-7","journal-title":"Ann Hematol"},{"issue":"1","key":"3636_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/bjh.14331","volume":"176","author":"HH Li","year":"2017","unstructured":"Li HH, Li F, Gao CJ, Huang WR, Bo J, Dou LP, Wang LL, Jing Y, Wang L, Li WJ, Yu L, Liu DH (2017) Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies. Br J Haematol 176(1):92\u2013100","journal-title":"Br J Haematol"},{"issue":"4","key":"3636_CR13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","volume":"97","author":"PA Rowlings","year":"1997","unstructured":"Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, Cahn JY, Calderwood S, Gratwohl A, Soci\u00e9 G, Abecasis MM, Sobocinski KA, Zhang MJ, Horowitz MM (1997) IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 97(4):855\u2013864","journal-title":"Br J Haematol"},{"issue":"4","key":"3636_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 40(4):381\u2013387","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"3636_CR15","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/bmt.2009.359","volume":"45","author":"L Scrucca","year":"2010","unstructured":"Scrucca L, Santucci A, Aversa F (2010) Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 45(9):1388\u20131395","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"3636_CR16","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1399-0012.2012.01618.x","volume":"26","author":"CH Yan","year":"2012","unstructured":"Yan CH, Liu DH, Xu LP, Liu KY, Zhao T, Wang Y, Chen H, Chen YH, Han W, Huang XJ (2012) Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transpl 26(6):868\u2013876","journal-title":"Clin Transpl"},{"issue":"7","key":"3636_CR17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/ctr.12561","volume":"29","author":"CH Yan","year":"2015","unstructured":"Yan CH, Xu LP, Liu DH, Chen H, Wang Y, Wang JZ, Wang FR, Han W, Liu KY, Huang XJ (2015) Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical SCT. Clin Transpl 29(7):594\u2013605","journal-title":"Clin Transpl"},{"issue":"8","key":"3636_CR18","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.bbmt.2017.04.028","volume":"23","author":"CH Yan","year":"2017","unstructured":"Yan CH, Liu QF, Wu DP, Zhang X, Xu LP, Zhang XH, Wang Y, Huang H, Bai H, Huang F, Ma X, Huang XJ (2017) Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus-host disease-guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory\/relapsed acute leukemia. Biol Blood Marrow Transplant 23(8):1311\u20131319","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03636-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03636-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03636-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T19:09:38Z","timestamp":1581448178000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03636-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,12]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["3636"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03636-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,12]]},"assertion":[{"value":"16 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}